PATIENT SAFETY
fantastic strengths we have across our health service, universities and industry.”
Digital transformation
Microsoft will bring a wealth of knowledge and services, including its deep expertise in confidential computation in public cloud. IBM will provide deep expertise in digital, technical service design and modelling, data capabilities, programme management and the life sciences sector. According to Cindy Rose, CEO of
Microsoft UK, clinical trials are fundamental in developing safe medical treatments. However, she warned that many are hampered by the lack of access to relevant patient information. “NHS DigiTrial will transform this process, ensuring healthcare professionals are able to accelerate clinical trials and bring much-needed treatments to market, faster,” she said. “Yet speed alone is not enough. Patients must trust their data is being held securely and only accessed appropriately. The use of Microsoft Azure will ensure all information utilised by NHS DigiTrial is integrated, managed securely and with all appropriate access controls. We are delighted to be involved in what is a great example of a public-private partnership to deliver better patient outcomes.” Dr Nicole Mather, life sciences lead, IBM Global Business Services, UK and Ireland, added that IBM’s collaboration with partners across health and life sciences will bring digital transformation to research, with the aim of getting more cutting-edge products, more quickly to NHS patients. “Working together we have the potential to help change lives and pave the way for new insights by unlocking the power of health data,” Nicole explained. “We will bring deep expertise in digital, technical service design and modelling, data capabilities and programme management to the partnership, collaborating to scale the transformational clinical trials capability developed through innovation from Oxford University and NHS Digital.” NHS DigiTrial will work with other hub teams, including Discover-NOW, a partnership led by Imperial College Health Partners. Discover-NOW has also submitted a successful bid for the Health Data Research Hub for Real World Evidence,
which will speed up research for new medicines, treatments and support quicker diagnoses and care provision. The perspectives of patients and clinicians will be sought throughout the development of the new Hubs. This will ensure that they stay tightly aligned to patient and clinical expectations and remain at the forefront of established best practice. The hub has also been welcomed by the National Institute for Healthcare Research and the Association of Medical Research Charities (AMRC) as a key contribution to the UK clinical trials offer.
Aisling Burnand, chief executive of the AMRC, said: “AMRC believes that every patient should be offered the opportunity to be involved in research, so we’re delighted to welcome this new data-driven clinical research feasibility and recruitment service. “Through the safe and secure management of health information the Hub will help patients across the length and breadth of England participate in clinical trials. We hope this will see more people gain faster access to new treatments.”
Improving patients lives
The pioneering data hubs aim to improve the lives of people with debilitating conditions, and will link up different types of health data and make it more easily accessible and user- friendly for research, while maintaining strict controls around data privacy and consent.
The Health Data Research Hubs are part of a four-year £37 million investment from the UK Government Industrial Strategy Challenge Fund (ISCF) announcedin November 2017 led by UK Research and Innovation, to create a UK-wide system for the safe and responsible use of health-related data on a large scale.
64 I
WWW.CLINICALSERVICESJOURNAL.COM
The potential benefits to patients include earlier diagnosis, the development of more effective treatments and more efficient management of the health service, all of which have the potential to improve outcomes, helping patients enjoy longer and healthier lives. Patients, researchers and clinicians will work together to explore the safe and ethical use of health data for research into specific diseases including cancer, Crohn’s disease and asthma. They will also enable access to data for trialling new treatments and support improvements in clinical care. Patients will be involved in decisions about how their data is used to ensure the benefits are returned to the NHS and the wider UK community, and existing rules for accessing data safely and securely will continue to apply. Sarah Brooke, Public Advisory Board member at Health Data Research UK, said: “The Public Advisory Board were keen to be involved in the selection process to raise awareness of the importance of public engagement and involvement in the Hubs. We see the Hubs playing a key role in engaging with the public about their work, raising public awareness of using data in research, scrutinising how the data is to be used and ensuring public trust remains at the heart of this important work.” The Health Data Research Hubs are
part of a four-year £37 million investment from the UK Government Industrial Strategy Challenge Fund (ISCF) announced in November 2017 led by UK Research and Innovation, to create a UK-wide system for the safe and responsible use of health-related data on a large scale. The hubs will also stimulate further economic growth through greater research activity.
Each hub was selected following an open competition by an independent panel involving patient and public representatives. They were assessed against criteria that included the potential for impact, the innovative uses of data, plans for involving patients and the public, and the value for public funding.
NOVEMBER 2019
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104
